

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

#### PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **June 2, 2005**

## PDI, INC.

*(Exact name of Registrant as specified in its charter)*

**DELAWARE**  
*(State or other jurisdiction  
of incorporation)*

**0-24249**  
*(Commission  
File Number)*

**22-2919486**  
*(IRS Employer  
Identification No.)*

**Saddle River Executive Centre  
1 Route 17 South,  
Saddle River, NJ 07458**  
*(Address of principal executive office)*

**(201) 258-8450**  
**Registrant's telephone number, including area code:**

---

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement.

On June 6, 2005, PDI, Inc. (the "Company") issued a press release announcing that on June 2, 2005, the Company sold its interest in In2Focus Sales Development Services Limited to United Drug (UK) Holdings Limited. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release dated June 6, 2005.

\* \* \* \* \*

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDI, INC.

By: /s/ CHARLES T. SALDARINI

---

Charles T. Saldarini, Vice Chairman  
and Chief Executive Officer

Date: June 6, 2005

---

## EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated June 6, 2005

---

**PDI Announces Sale of Interest in In2Focus Sales Development Services Limited**

SADDLE RIVER, N.J., June 6 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII) today announced the sale of its interest in In2Focus Sales Development Services Limited (In2Focus), a U.K. based specialist sales organization. PDI acquired a minority interest in In2Focus in 2000.

The net sale proceeds to PDI are approximately \$4.4 million after transaction expenses. PDI's original investment totaled approximately \$1.85 million. As of December 31, 2001, PDI wrote the investment down to zero for book purposes, and fully reserved against the deferred tax asset associated with the write down.

In2Focus was acquired by United Drug (UK) Holdings Limited, a company incorporated in England.

Steven K. Budd, President, Global Sales and Marketing Services Group, said, "We are pleased that we had a chance to work with In2Focus over the last few years and to contribute to their success. Our relationship enabled us to understand and evaluate the U.K. and European markets. We have decided that at the present time, it is in our best interests to grow our leadership position in the U.S. where we believe we have the greatest opportunity to create shareholder value."

**About PDI**

PDI, Inc. (Nasdaq: PDII) is a leading provider of outsourced sales and marketing services to the biopharmaceutical and medical devices and diagnostics industries. PDI's comprehensive set of next-generation solutions is designed to increase its clients' strategic flexibility and enhance their efficiency and profitability. Headquartered in Saddle River, NJ, PDI also has offices in Pennsylvania and Illinois.

PDI's sales and marketing services include dedicated, shared, clinical and combination sales teams; marketing research and consulting; medical education and communications; talent recruitment; and integrated commercial solutions from pre-launch through patent-expiration. The company's experience extends across multiple therapeutic categories and includes office and hospital-based initiatives.

PDI's commitment is to deliver innovative solutions, excellent execution and superior results to its clients. Through strategic partnership and client-driven innovation, PDI maintains some of the longest sales and marketing relationships in the industry. Recognized as an industry pioneer, PDI continues to innovate today as a thought-starter for the outsourcing of sales and marketing services.

For more information, visit the Company's website at <http://www.pdi-inc.com> .

For more information contact:

Stephen P. Cotugno  
Executive Vice President-Corporate Development  
PDI, Inc.  
201.574.8617

SOURCE PDI, Inc.

-0-

06/06/2005

/CONTACT: Stephen P. Cotugno, Executive Vice President-Corporate Development of PDI, Inc., +1-201-574-8617/

/Web site: <http://www.pdi-inc.com> /

---